Renal Insufficiency, Chronic Clinical Trial
— NeurovExOfficial title:
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | October 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria for Chronic Kidney Disease Patients: - Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation - Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months - Does not exercise regularly (defined as exercising less than 20 minutes twice per week) - Willing and able to cooperate with the study protocol Inclusion Criteria for Control Study Participants: - Does not exercise regularly (defined as exercising less than 20 minutes twice per week) - Willing and able to cooperate with the study protocol Exclusion Criteria: - severe CKD (eGFR<15 cc/minute) - ongoing drug or alcohol abuse - diabetic neuropathy - any serious systemic disease that might influence survival - severe anemia with hgb level <9 g/dL - clinical evidence of congestive heart failure or ejection fraction below 35% - symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history - treatment with central alpha agonists (clonidine) - uncontrolled hypertension with BP greater than 170/100 mm Hg - low blood pressure with BP less than 100/50 - pregnancy or plans to become pregnant - current treatment with monoamine oxidase (MAO) inhibitors - inability to exercise on a stationary bicycle |
Country | Name | City | State |
---|---|---|---|
United States | Emory University Hospital | Atlanta | Georgia |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Atlanta VA Health Care System | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in functional sympatholysis | Muscle oxygenation during exercise and sympathoexcitation will be measured. | Baseline, Week 12 | |
Primary | Change in vascular alpha 1 adrenergic responsiveness | Changes in vascular diameter in response to phenylephrine will be measured. | Baseline, Week 12 | |
Primary | Change in exaggerated pressor responses during exercise | Blood pressure and sympathetic responses during exercise will be measured. | Baseline, Week 12 | |
Secondary | Renal artery resistance during exercise | Renal artery blood flow will be measured. | Baseline, Week 12 | |
Secondary | Change in endothelial function | Endothelial function using peripheral arterial tonometry will be measured. | Baseline, Week 12 | |
Secondary | Change in vascular stiffness | Vascular stiffness using applanation tonometry. | Baseline, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 | |
Completed |
NCT01711853 -
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
|
Phase 1 |